$13.71
Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
Bears are Losing Control Over Amarin (AMRN), Here's Why It's a 'Buy' Now
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
Overview
52-week range
$12
$21
22% of range
Avg surprise (last 2)
+95.9%
Avg reaction (last 1)
-0.1%
0% positive
Latest IV / EM
81%
EM ±18.4% · $14 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $-0.03 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-0.02 | — | — | — | — | financials |
| Wed Jul 30, 2025 | Jun/2025 | $-0.03 | $-0.66 | +95.5% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $-0.04 | $-1.12 | +96.4% | — | -0.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.06 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | — | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.02 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.05 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.04 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Jul 29, 2026 | Jun/2026 | BMO | -$0.21 | -$0.03 | -600.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | $18M | — | $22M | $50M | $25M | — | $16M | $43M |
| Operating income | $-11M | — | $-11M | $-16M | $-17M | — | $-25M | $-524,000 |
| Net income | $-11M | — | $-8M | $-14M | $-16M | — | $-25M | $2M |
| EPS (diluted) | $-0.03 | — | $-0.02 | $-0.03 | $-0.04 | — | $-0.06 | — |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $131M | $135M | $123M | $148M | $120M | $121M | $157M | $216M |
| Inventory | $184M | $196M | $185M | $171M | $159M | $166M | $224M | $239M |
| Total current assets | $626M | $650M | $628M | $607M | $573M | $595M | $650M | $702M |
| Total assets | $646M | $671M | $660M | $670M | $656M | $685M | $751M | $800M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $196M | $211M | $201M | $205M | $182M | $199M | $219M | $248M |
| Total equity | $449M | $459M | $459M | $465M | $474M | $486M | $531M | $552M |